Clinical Trials Browser

Recruiting × Interventional × HER2-positive Gastric Cancer × Clear all

NCT06764875 2026-03-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT06572319 2024-08-27

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

Phase 1/2 Recruiting

Gastrointestinal

HER2-positive Gastric Cancer